Birecik State Hospital, Sanliurfa, Turkey.
Med Oncol. 2012 Jun;29(2):466-71. doi: 10.1007/s12032-011-9873-4. Epub 2011 Mar 4.
Class-II human leukocyte antigens (HLA) present tumor antigenic peptides on the cell surface in order to be recognized by T lymphocytes. Thereby, these molecules can play an important role in the immune response to breast cancer tumor antigens. The aim of this study was to determine the relation between breast cancer and HLA class-II alleles in Turkey. The study groups consisted of 69 breast cancer patients and 45 healthy controls. Typing of HLA-DRB1 and HLA-DQB1 from DNA samples was performed by Sequence Specific Oligonucletide Hybridisation. Significant negative correlations were observed between HLA-DRB1 03 and HLA-DQB1 02 alleles and breast cancer (p1 = 0.019; p2 = 0.019) and also between HLA-DQB1 02 allele and postmenopausal breast cancer (P = 0.022) and c-erb-B2 positivity (P = 0.038). Furthermore, there was a significant positive correlation between HLA-DRB1 13 and HLA-DQB1 06 alleles and progesteron receptor positivity (p1 = 0.012; p2 = 0.001); and a significant negative correlation between HLA-DQB1 03 allele and progesteron receptor positivity (P = 0.009) in breast cancer. Additionally, another significant positive correlation was seen between HLA-DRB1 04 allele and c-erb-B2 positivity (P = 0.036). As a result, while HLA-DRB1 03, HLA-DQB1 02, HLA-DRB1 13, and HLA-DQB1 06 alleles were found to be involved in protectiveness against breast cancer and good prognosis; HLA-DQB1 03 and HLA-DRB1 04 alleles were found to be involved in poor prognosis. In conclusion, by determining allele types showing predisposition to breast cancer, a systematical screening and follow up systems can be developed for patients who are at high risk.
Ⅱ类人白细胞抗原(HLA)在细胞表面呈递肿瘤抗原肽,以便被 T 淋巴细胞识别。因此,这些分子在乳腺癌肿瘤抗原的免疫反应中可以发挥重要作用。本研究旨在确定土耳其乳腺癌与 HLA Ⅱ类等位基因的关系。研究组由 69 例乳腺癌患者和 45 例健康对照组成。从 DNA 样本中对 HLA-DRB1 和 HLA-DQB1 进行基因分型,采用序列特异性寡核苷酸杂交法。HLA-DRB103 和 HLA-DQB102 等位基因与乳腺癌显著负相关(p1=0.019;p2=0.019),HLA-DQB102 等位基因与绝经后乳腺癌(P=0.022)和 c-erb-B2 阳性(P=0.038)也显著负相关。此外,HLA-DRB113 和 HLA-DQB106 等位基因与孕激素受体阳性之间存在显著正相关(p1=0.012;p2=0.001);HLA-DQB103 等位基因与孕激素受体阳性之间存在显著负相关(P=0.009)。此外,HLA-DRB104 等位基因与 c-erb-B2 阳性之间也存在显著正相关(P=0.036)。因此,虽然 HLA-DRB103、HLA-DQB102、HLA-DRB113 和 HLA-DQB106 等位基因被认为与乳腺癌的保护作用和良好预后有关;但 HLA-DQB103 和 HLA-DRB104 等位基因与不良预后有关。总之,通过确定易患乳腺癌的等位基因类型,可以为高危患者制定系统的筛查和随访系统。